JCB logo
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1083/jcb.1844iti1
The Journal of Cell Biology, Vol. 184, No. 4, 464-
The Rockefeller University Press, 0021-9525 $30.00
© Williams
This Article
Right arrow Full Text (PDF, 1190K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Williams, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

In This Issue

How WldS neuroprotects



Figure 1
The chimeric WldS protein (top) protects neurons from degrading after insult, and it needs both its domains to do so.

The neuronal guardian protein, WldS, like a true superhero, gained its powers by chance mutation. Now, thanks to two studies, we are closer to understanding how WldS exerts its protective force.

The slow Wallerian degeneration (WldS) protein and its neuroprotective powers came to exist thanks to a spontaneous mutation that fused the genes for Nmnat1 (a NAD+ synthesizing enzyme) and Ube4b (a ubiquitination factor). The mutation was discovered by Coleman et al. in 1998 as the reason why a particular mouse strain, described by Hugh Perry a decade earlier, has exceptionally resistant neurons. Given WldS's ability, and thus its therapeutic potential for neurodegenerative diseases, it has become the focus of intense scrutiny.

Two groups, Conforti et al. and Avery et al., have now pulled apart WldS to learn the secret of its power. They show that both the enzymatic function of Nmnat1 and the ability of the Ube4-derived portion to bind a protein called VCP (or TER94 in flies) are indispensible for WldS's neuroprotective effect. VCP is abundant throughout the cell whereas WldS localizes primarily to the nucleus. However, when Avery et al. expressed mouse Nmnat3—a relative of Nmnat1 with the same enzyme activity, but that in fly neurons fails to localize to the nucleus—it conferred WldS-like protection. Both groups therefore believe that binding of WldS to VCP localizes Nmnat1 enzyme function to a region of the cytoplasm it wouldn't normally encounter. The question now is, where. RW


References

Avery, M.A., et al. 2009. J. Cell Biol. 10.1083/jcb.200808042.[Abstract/Free Full Text]

Conforti, L., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200807175.[Abstract/Free Full Text]



Ruth Williams

ruth.williams{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 1190K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Williams, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents